Inhibitors of bone resorption, such as bisphosphonates and denosumab (Warren et al., 2021; McKiernan et al., 2014), decrease the overall bone remodeling rate and can be expected to worsen the mineral metabolic state since HPP patients are at risk of deficient mineralization and osteomalacia due to their ALP deficiency. The gene discussed is ALPP; the disease is osteomalacia.